First, in patients with lung adenocarcinoma harboring sensitive EGFR mutation receiving first-generation EGFR-TKIs, prior use of β-blockers was independently associated with a better 2-year TTD and 4-year OS compared with nonusers. This evidence concerns the gene EGFR and lung adenocarcinoma.